- Home
- RLAY vs EYPT Comparison
RLAY vs EYPT Comparison
Compare RLAY & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- EYPT
- Stock Information
- Founded
- RLAY 2015
- EYPT 1987
- Country
- RLAY United States
- EYPT United States
- Employees
- RLAY N/A
- EYPT N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- RLAY Health Care
- EYPT Industrials
- Exchange
- RLAY Nasdaq
- EYPT Nasdaq
- Market Cap
- RLAY 490.3M
- EYPT 484.4M
- IPO Year
- RLAY 2020
- EYPT 2005
- Fundamental
- Price
- RLAY $3.18
- EYPT $8.42
- Analyst Decision
- RLAY Strong Buy
- EYPT Strong Buy
- Analyst Count
- RLAY 11
- EYPT 8
- Target Price
- RLAY $18.40
- EYPT $24.75
- AVG Volume (30 Days)
- RLAY 1.5M
- EYPT 898.9K
- Earning Date
- RLAY 08-05-2025
- EYPT 08-06-2025
- Dividend Yield
- RLAY N/A
- EYPT N/A
- EPS Growth
- RLAY N/A
- EYPT N/A
- EPS
- RLAY N/A
- EYPT N/A
- Revenue
- RLAY $7,679,000.00
- EYPT $56,042,000.00
- Revenue This Year
- RLAY $14.31
- EYPT N/A
- Revenue Next Year
- RLAY N/A
- EYPT N/A
- P/E Ratio
- RLAY N/A
- EYPT N/A
- Revenue Growth
- RLAY N/A
- EYPT 12.04
- 52 Week Low
- RLAY $1.78
- EYPT $3.91
- 52 Week High
- RLAY $10.72
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- RLAY 55.48
- EYPT 59.17
- Support Level
- RLAY $2.98
- EYPT $8.50
- Resistance Level
- RLAY $3.48
- EYPT $9.60
- Average True Range (ATR)
- RLAY 0.25
- EYPT 0.59
- MACD
- RLAY -0.00
- EYPT -0.01
- Stochastic Oscillator
- RLAY 58.45
- EYPT 52.61
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.